News & Events about Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on January 10, 2023, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 23,900 shares of common stock and 12,000 restricted stock units (RSUs) to four...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview of the companys plans, estimated revenue and net product sales for Q4 and full year 2022 ahead of its presentation at the 41st Annual J.P. Morgan Healthcare Conference. 2022 was a year of strong commercial performance and continued...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows...
Ticker Report
2 months ago
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM Get Rating) Director Niall Odonnell sold 174,121 shares of the companys stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $19.99, for a total transaction of $3,480,678.79. Following the ...